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Abstract
Artesunate (ART) is widely used for the treatment of malaria, but the mechanisms of its effects on
parasitized red blood cells (RBCs) are not fully understood. We investigated ART's influence on
the dynamic deformability of red blood cells infected with ring-stage Plasmodium falciparum
malaria (iRBCs) in order to elucidate its role in cellular mechanobiology. The dynamic
deformability of red blood cells was measured by passing them through a microfluidic device with
repeated bottleneck structures. The quasi-static deformability measurement was performed using
micropipette aspiration. After ART treatment, microfluidic experiments showed 50% decrease in
iRBC transit velocity whereas only small (~10%) velocity reduction was observed among
uninfected RBCs (uRBCs). Micropipette aspiration also revealed ART-induced stiffening in RBC
membranes. These results demonstrate, for the first time, that ART alters the dynamic and quasi-
static red blood cell deformability, which may subsequently influence blood circulation through
microvasculature and spleen cordal meshwork, thus adding a new aspect to artesunate's
mechanism of action.
Introduction
Malaria is the most deadly parasitic disease which affects 200 million people worldwide and
accounts for nearly one million annual deaths 1. The most virulent malarial parasite
Plasmodium falciparum can lead to severe complications and has the highest mortality
rate 2. During its asexual stage, P. falciparum infects red blood cells (RBCs), which then
undergo notable morphological and rheological changes from the ring stage to trophozoite
and finally schizont stage, constituting a 48 h asexual reproduction cycle 3. Cyclic febrile
attack is a characteristic clinical feature of P. faciparum malaria, which corresponds to the
release of merozoites in circulation following iRBC rupture in the late schizont stage.
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Apart from cerebral malaria, malarial anemia is the most frequent and severe syndrome of
falciparum malaria 4. Massive loss of RBCs cannot be entirely attributed to the destruction
of infected RBCs (iRBCs), which usually constitute only a small fraction of total RBCs in
malaria patients. Instead, the major cause of malarial anemia is believed to be the excessive
loss of uninfected RBCs (uRBCs), mostly in the spleen and/or the liver 5. Malaria-related
dyserythropoiesis is likely a minor factor because complete removal of erythropoiesis brings
about only a minor decrease in RBC population 6. On the other hand, it has been suggested
that uRBCs exposed to the parasites are slightly less deformable, and/or decorated with
parasite molecules 7, both of which could potentially lead to splenic retention and clearance
of a large number of uRBCs, exacerbating malarial anemia. However, the exact causes and
mechanisms of malarial anemia are yet to be firmly established.
Several studies indicate that RBC filtration in the spleen is critical to influencing diverse
pathophysiological outcomes of malaria 8. Splenomegaly (enlarged spleen) is a clinical
consequence of malaria infection. The narrow splenic inter-endothelial slits (~1 2 μm in
height) provide a stringent mechanical filter through which only RBCs with adequate
deformability can pass. In the later (trophozoite and schizont) stages of malaria, iRBCs can
be up to 50 times stiffer than uRBCs 9. However, in the earlier ring-stage (which occurs
within the first 24 h of intra-erythrocytic invasion of the parasite), iRBCs are only
moderately stiffer than uRBCs. Although the ring stage is the only asexual parasite stage
that can be found in blood circulation, a substantial (~50%) proportion of the ring-stage
iRBCs are retained by the human spleen, as demonstrated in the experiment using isolated
human spleens 10. The Ring-infected Erythrocyte Surface Antigen (RESA), is one of the
parasite derived-proteins responsible for the reduction of ring-stage iRBC membrane
deformability 11.
Clinical studies show that malaria patients with artesunate (ART) treatment exhibit a more
rapid decline in the parasitemia and also that the accelerated parasite clearance is delayed in
splenectomized patients 12. The involvement of spleen is therefore believed to be
responsible for rapid parasite clearance after ART drug treatment 5. The in vivo parasite
clearance following ART treatment has often been attributed to a process known as ‘pitting’,
whereby spleen removes intraerythrocytic parasites without destructing the host RBCs13, 14.
However, it is unclear whether pitting is the main mechanism of splenic parasite clearance.
Studies by Newton et al. noted that the average lifespan of pitted RBCs (i.e. RESA RBC) is
only 183 hours, significantly shorter compared to normal RBC life of 1027 hours 15.
Furthermore, ART treatment was found to further shorten the pitted RBC life, suggesting
that other mechanisms facilitating splenic parasite clearance may exist. Since spleen is also
known as a “mechanical filter” that removes old and stiffened RBCs from
microcirculation 5, 16, the rapid splenic parasite clearance after ART treatment might be
attributed to ART altering the mechanical properties of iRBCs and possibly of uRBCs.
However, there is currently a lack of experimental evidence to confirm such an effect of
ART on RBC deformability 14.
Experiments show that subtle changes in RBC deformability may lead to a significant shift
in splenic RBC retention efficiency 5, 17. A sensitive single cell deformability cytometry for
characterizing the dynamic deformability of both uRBCs and iRBCs is therefore essential
for understanding malaria pathophysiology. Bulk cell measurements such as
ektacytometry 18, 19, which describe the averaged values of RBC deformability through
geometric estimates, do not provide reliable measures of individual cells’ mechanical
properties. On the other hand, most of the established tools for single cell deformability
measurements including micropipette aspiration 20, 21, atomic force microscopy 22, and
optical tweezers 11 require extensive experimental effort to extract reliable information for
large populations of cells. More importantly, such measurements impose quasi-static loads
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to attain notable deformation, and the resulting information may not be directly applicable to
the more realistic situation involving dynamic cell deformation. Furthermore, static
deformability of RBCs is characterized by the shear and bending moduli of the cell
membrane, whereas dynamic deformability can be influenced by additional factors such as
membrane viscosity and cell shape. When RBCs circulate in blood capillaries and spleen
cordal meshwork, they undergo a complicated, time-dependent deformation process.
Therefore, a more straightforward and direct way to evaluate the amenability of RBCs to
pass through constrictions in the spleen and microcapillary blood vessels is to simulate such
in vivo RBC deformations during circulation using microfluidic artificial filter structures 23.
In contrast to conventional filtration system, in which the RBC “filterability” is evaluated
directly by the percentage of cells that pass through, the microfluidic system employed in
this work characterizes single RBC deformability via its transit velocity through repeated
bottleneck structures while facilitating such measurements on a large population of cells.
In this paper, the influence of ART on RBC deformability in the pathology of P. falciparum
malaria is evaluated using two approaches: a microfabricated deformability cytometer that
mimics in vivo RBC microcirculation24 and micropipette aspiration that measures RBC
membrane stiffness. Besides, ART's effects on the mechanical properties of iRBCs were
further assessed by treating the iRBCs in combination with pentoxifylline (PTX), a possible
adjunctive therapy for cerebral malaria2527.
Materials and Methods
Microfluidic device
The microfluidic device was designed with layout program and it consists of 500 μm × 500
μm inlet/outlet reservoirs and parallel capillary channels with triangular pillar arrays (Figure
1A). Two different inter-pillar gap sizes of 3.0 and 4.0 μm were tested for optimum
deformation condition. Detailed fabrication steps was described by Bow et al 24.
Parasite culture
P. falciparum 3D7A parasites used in this study were obtained from Malaria Research and
Reference Reagent Source, American Type Culture Collection. Parasites were cultured as
previously described 28. Cultures were synchronized at the ring-stage by sorbitol lysis 29 two
hours after merozoite invasion.
Artesunate drug treatment
The stock ART solution (1.25 mg/ml) was prepared by dissolving ART powder (Sigma
A3731) in aqueous sodium bicarbonate. A highly synchronized culture of 6 hour old rings
with ~ 15% parasitemia was resuspended at 0.1% hematocrit in malaria culture medium
containing various concentration of ART drug. In the control group, sodium bicarbonate
solution without ART was added. Both drug and control groups were incubated at 37 °C for
2-6 h.
Solution preparation
Phosphate buffered saline (PBS) with 1% w/v Bovine Serum Albumin (BSA) (Sigma-
Aldrich, St. Louis, MO) was fresh made on every experimental day as stock solution. For
experiments measuring healthy RBC deformability, fresh whole blood (Research Blood
Components, Brighton, MA) was diluted 100 times with PBS/BSA buffer. For experiments
measuring malaria infected cells, 1ml of cultured cells were centrifuged at 350g for 5 min; 1
μl of the pellet was then aliquot to 200 μl stock solution.
Huang et al. Page 3













To distinguish infected cells from uninfected RBCs, 10 μl of 1 × 10-6 M thiazole orange
(Invitrogen, Carlsbad, CA), which stains the RNA of the cell, was added to the
aforementioned 200 μl iRBC containing solution 20 min before the experiment. The iRBCs
would appear fluorescent under the GFP filter set whereas the uRBCs were seen as dark
shadows.
Experimental protocol for microfluidics
To accurately control the ambient temperature, the microscope surface was replaced by a
heating chamber (Olympus), which was preheated to a desired temperature for 30 min
before the beginning of every experiment. Meanwhile, the PBS/BSA stock solution was
injected into the device to coat the PDMS walls to prevent adhesion. This filling step needs
not to be done inside the heating chamber, but the PBS/BSA filled device needed to be
placed into the heating chamber at least 5 min before loading 5 μL of diluted blood sample.
During temperature calibration phase, a thermal meter was used to probe the exact
temperature inside the heating chamber. When the temperature needed to be adjusted to a
different value, at least 5 min of waiting time was required to ensure a new stable ambient
temperature.
The microfluidic device was driven by a constant pressure gradient across. The inlet
reservoir was connected to a vertically held 60-ml syringe which was partially filled with
PBS/BSA buffer solution. A CCD camera (Hamamatsu Photonics, C4742-80-12AG, Japan)
was connected to the inverted fluorescent microscope (Olympus IX71, Center Valley, PA)
to capture the movement of the RBCs in the microchannels. Images were automatically
acquired by IPLab (Scanalytics, Rockville, MD) at 100 ms time interval and the post-
imaging analysis was done using imageJ. The velocity of individual RBCs was defined as
the distance the cells moved divide by the time in seconds. To better illustrate drug-induced
percentage change in iRBC/uRBC velocity, the term “normalized velocity” was adopted.
Normalized velocity was obtained by dividing the measured velocity of individual RBCs
from various experimental conditions by the average uRBC velocity of the control group on
the same experimental day.
Experimental protocol for micropipette aspiration
Micropipette Aspiration was carried out using an inverted optical microscope (Olympus
IX71) equipped with a micromanipulator (Eppendorf Transferman NK 2), a heating stage
(Linkam Scientific Instruments) and an objective heater (Tokai Hit thermo plate). Pipettes
were drawn from borosilicate glass tubing (Sutter Instrument Model P-2000) and cut open
(Narishige MF-900) prior to mounting to the micromanipulator. The pipette diameter was
kept at 1.0 μm throughout the experiments. Prior to the measurements, the cell chamber was
preheated to 37 °C and flushed with the PBS-BSA stock solution with the glass pipette
readily mounted and inserted. After the temperature of the stock solution equalized to 37 °C,
1 μl of cells were injected into the cell chamber. Subsequently, the aspiration pressure was
increased to 100Pa at a rate of 0.5 Pa/s measuring one cell at a time. Images of each
aspirated cell were captured at a rate of 1/s using a high-resolution digital camera (Olympus
DP72). The maximum time span before the whole sample was replaced by a fresh sample
was 1 h. From the high-resolution recordings, the leading edge of the aspired RBC
membrane was tracked manually for calculating the elastic shear modulus using the
spherical cap model 21.
Statistical analysis
Two-tailed Student's t-tests were used to compare the microfluidic results and the shear
modulus values at various test conditions.
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The microfluidic device comprises a series of equally spaced triangular pillar arrays with
gap sizes ranging from 2.5 to 4 μm (Figure 1 illustrates the system with 4 μm gap size). The
gap sizes were designed to impose mechanical constraints similar to those encountered by
the RBCs (with an average diameter of about 8 μm) when traversing blood capillaries and
splenic meshwork. Driven by a constant pressure gradient that is smaller than the Pa/μm
level, RBCs undergo large elastic deformation at each constriction while traversing the
channel 24. The dynamic deformability of RBCs is then characterized by their velocity at a
given pressure gradient which signifies their ability to deform repeatedly in order to pass
through many successive constrictions.
Figure 1B presents sequential freeze-frame images of an uRBC moving inside the
microchannel. The velocity of individual RBCs can then be derived by recording the time of
passage of each cell through 10 constrictions in series (i.e. for a total travel distance of 200
μm). The typical pressure gradient (~0.5 Pa/μm) and shear rate (~100 s-1) applied in this
device as well as the resulting RBC flow rate (20 - 200 μm/s) are comparable to those of
physiological flows 30; they are also of the same order of magnitude as RBCs passing
through splenic inter-endothelial slits (IES) 31.
Time-dependent effects of ART on the dynamic deformability of iRBCs
Ring-stage P. falciparum cultures were exposed to ART, an artemisinin derivative. The
deformability of both iRBCs and co-cultured uRBCs was measured 2, 4 and 6 h after ART
drug treatment. Cultures of iRBCs and uRBCs without ART treatment were used as control.
All experiments were performed at 37 °C.
Figure 2A demonstrates pronounced decrease in iRBC velocity after 4 h of ART exposure.
Compared to the control iRBCs (40 μm/s), the average transit velocity of ART-exposed
iRBCs was halved (20 μm/s), indicating a statistically significant reduction of the dynamic
deformability induced by ART (p < 0.001). On the other hand, a much smaller decrease in
the average transit velocity of uRBCs was observed after ART exposure.
To assess the time-dependent effects of ART treatment, the dynamic deformability
measurements were performed after 2, 4, and 6 h of ART exposure. The results are given in
Figure 2B. While no significant difference in the average iRBC velocity could be observed
after 2 h ART incubation, iRBC velocity dropped significantly by approximately 40% after
4 h of ART exposure (p < 0.001).
The differential deformability between uRBCs and iRBCs was previously noted as the key
parameter for efficient splenic filtration of iRBCs 5, 10, 32, 33. The deformability difference
between uRBCs and iRBCs can be assessed through the index, Rs:
Here X1 and X2 are the mean values of velocities of iRBCs and uRBCs, respectively, and σ1
andσ2 denote the standard deviations of velocities of iRBCs and uRBCs, respectively. A
higher Rs value implies larger separation between the velocities of iRBCs and uRBCs.
While in both control and ART-exposed groups the iRBC velocities are significantly slower
than that of cocultured uRBCs (p < 0.001), the velocity separation resolution Rs was
enhanced by 2.3 times from 0.33 to 0.77 after ART exposure. Additionally, the average
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iRBC velocity after ART exposure was 3.13σ2 (σ2: standard deviation of uRBC velocity
distribution) away from the average uRBC velocity. This result suggests a more specific
dynamic deformability differentiation between uRBCs and iRBCs after ART exposure,
which may consequently lead to more efficient splenic parasite clearance.
Concentration-dependent ART effect on dynamic deformability of iRBCs
The in vivo serum concentration of ART varies with time after injection 34, 35. Typically, the
half-life of ART in patients is approximately 3 h with peak serum concentration of 0.1 μg/
ml. Therefore, the dynamic deformability assay was further expanded to different
concentrations. Figure 2D indicates that from 0.01 μg/ml to 0.1 μg/ml, there is no
statistically significant dose dependency on ART induced alteration of the RBCs
deformability.
Time-dependent ART effect on the quasi-static deformability of iRBCs
In parallel with the microfluidic experiments, micropipette aspiration of iRBCs and uRBCs
was carried out. The membrane elastic properties were determined before and after ART
exposure of RBCs for 2, 4 and 6 h. As control, cultures of iRBCs and uRBCs without
exposure to ART were measured. All measurements were performed at 37°C.
Figure 3 summarizes the membrane elastic shear moduli of uRBCs and iRBCs before and
after exposure to ART. The mean values for the elastic shear moduli of the iRBCs were
consistently 30% to 40% higher than the moduli of their uninfected counterparts. Solely
after incubating with ART for 2 h, the mean elastic shear moduli for both iRBCs and uRBCs
increased by 10% to 20% with p-value of 0.06, which is approximately at the threshold level
of statistical significance of p = 0.05.
Exposure to ART results in an increase of the membrane elastic shear modulus of both
uRBCs and iRBCs (Figure 3). For uRBCs the relative increase in mean elastic shear
modulus is 20% ± 2% independent of the incubation time. For iRBCs the maximum relative
increase was measured to be 20% after 4 h ART incubation.
Effect of Pentoxifylline on the dynamic deformability of iRBCs
Pentoxifylline (PTX), a hydroxyl radical scavenger 19, 36, 37, is believed to be able to
improve impaired blood flow. Several studies also suggest it can be used as an ancillary
treatment for severe falciparum malaria, in combination with ART. In this section, the effect
of PTX alone, as well as the combined effect of PTX and ART on the dynamic
deformability of P. falciparum-infected RBCs are studied in vitro. All experiments were
performed at 37 °C.
Figure 4A demonstrates that PTX has no statistically significant effect on the deformability
of ring-stage iRBCs even after 4 h of incubation at a concentration of 100 μg/ml. The
average transit velocity of iRBCs after PTX treatment was 33 μm/s, which was very similar
to that of the control sample (34 μm/s, p = 0.54). Simultaneous measurements were also
performed on co-cultured uRBCs. Whereas the average uRBC velocity in the control sample
was 43 μm/s, the value after PTX treatment was statistically different (46 μm/s, p = 0.034),
exhibiting a significant albeit mild increase on the dynamic deformability of uRBCs.
The effect of PTX on the difference in response between uRBC and iRBC was calculated in
the similar way as introduced before. The Rs value for the control sample was 0.33
compared to 0.40 after PTX treatment. The result suggests a marginal (if any) effect of PTX
drug on RBC deformability.
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Typical clinical dosage of PTX is between 5 and 20 μg/ml. To investigate whether the effect
of PTX on uRBCs is dose-dependent, the co-cultured uRBCs were exposed to 20 μg/ml and
100 μg/ml PTX for 2 h. Compared to the control sample (42.79 μm/s), the average uRBC
velocity exhibited significant improvement at both concentrations (52.03 μm/s and 51.33
μm/s, p < 0.01) and no statistically significant concentration dependence could be
concluded. Figure 4B suggested that the effect of PTX on uRBCs was not dose-dependent
(p=0.67) in the concentration range between 20 to 100 μg/ml.
After 2 h incubation with PTX, the uRBC dynamic deformability seemed to be slightly
enhanced (from 42.79 to 52.03 μm/s). The effect remained for incubation up to 6 h (Figure
4C). Simultaneous deformability measurement was obtained for iRBCs and no statistical
significant effect was observed up to 6 h PTX incubation (Figure 4D).
The combined effect of PTX and ART is shown in Figure 4E. Compared with ART only
experiments, PTX does not seem to provide additional influences to the dynamic
deformability of both iRBC and uRBC when applied in combination with ART.
Discussion
It is widely accepted that ring-stage P. falciparum parasites are the only asexual intra-
erythrocytic parasite forms able to travel through human circulation without being
recognized by the human host. Antimalarial drugs affecting ring-stage iRBC membrane
mechanical properties would help the host with early identification of parasitized red blood
cells, and consequently their effective clearance by the human spleen.
In the present study we explored the effect of two different drugs (artesunate and
pentoxifylline) on the microcirculatory velocity of RBCs after malaria infection. Both drugs
are used alone or in combination for the treatment of p. falciparum malaria: artesunate
(ART) is known to facilitate splenic parasite clearance 38, and pentoxifylline (PTX) has been
suggested as an effective adjunctive therapy with ART 39, but their relevant effects on the
RBC mechanical properties are not yet well understood.
Our results demonstrate that ART treatment significantly stiffens ring-stage iRBCs based on
both quasi-static and dynamic single cell deformability assays. Additionally, our
microfluidic set up mimicking RBC microcirculatory behavior revealed that ART has a
significant impact on the velocity separation resolution between iRBCs and uRBCs. Both
observations suggest the role of ART in influencing the dynamic circulation of iRBCs and
uRBCs. Since human spleen is well known as a “mechanical filter” that removes old and
abnormal RBCs16, and splenic retention of artificially hardened uRBCs has been
demonstrated by Buffet et al. using an ex vivo spleen8, 32, we speculate ART induced
alternation in RBC membrane stiffness and dynamic microcirculatory behavior would have
a significant effect on splenic RBC filtration24.
Pentoxifylline, on the other hand, was initially developed to improve blood flow in the
microvasculature 39. It was suggested as a possible ancillary therapy for cerebral malaria but
clinical trials showed conflicting results 26, 40. In this study, we attempted to evaluate how
PTX and PTX-ART combinational therapy impact on the microcirculatory behavior of
RBCs infected with P.falciparum malaria. The microfluidic based dynamic deformability
assay with ring-stage iRBCs treated with PTX suggested a marginal albeit significant
enhancement on uRBC deformability (p<0.05). This result is consistent with several other
deformability studies using different measurement platform 36, 41. However, we did not
observe any significant effect of PTX on iRBC deformability. Experiments with ART-PTX
combinational therapy did not reveal any beneficial effect of adding PTX.
Huang et al. Page 7













Currently the underlying molecular mechanism of ART-induced RBC stiffening is
undetermined. Clinical studies revealed that the drug action is mainly attributed by the
endoperoxide-bridge. Deoxyartemisinin, an Artemisinin analog lacking the endoperoxide
bridge, is clinically proven devoid of antimalarial activity 42, indicating the important role of
peroxide in Artemisinin's and its derivative ART's drug action. Artesunate induced oxidative
stress, a likely consequence due to its endoperoxide structure, was also suggested by
Krungkrai et al to be the key for the drug's antimalarial activity 43. It is therefore possible
that the endoperoxide-bridge could also be responsible for ART-induced RBC stiffening.
This is confronted by our microfluidic experiments with iRBCs treated with
deoxyartemisinin, which revealed that deoxyartemisinin has no effect on the deformability
of both uRBCs and iRBCs. (S2)
It is noted that due to the complex nature of RBC deformability, different measurement tools
could lead to different experimental observations. For example, prior deformability
measurements by rotational ektacytometry reported that up to 4 h ART exposure would not
affect uRBC deformability 14, but our microfluidic and micropipette experiments showed
significant uRBC stiffening after 2 h ART treatment. Additionally, the ektacytometry
measurement suggests that ≥ 2 h ART exposure would result 20% reduction in the
deformability separation between healthy and ring samples; our micropipette data showed
that the deformability separation between uRBCs and iRBCs dropped from 0.36 to 0.18 (i.e.
50% drop) only at 2 h time point, and then restored back to 0.40 and 0.51 respectively after
4 h and 6 h ART treatment. Similarly, the microfluidic system measured 14% drop (from
0.30 to 0.36) in the deformability separation only at 2 h incubation time point and the
separation would then increase to 0.54 and 0.55 after 4 h and 6 h ART treatment
respectively. The exact cause accounting for the discrepancies among different measurement
tools remains unclear. It is likely that the difference could come from the different
formulations of deformability, such as “elongation index” in ektacytometry, “membrane
shear modulus” in micropipette aspiration, and “transit velocity” in microfluidics. Compared
to the microfluidic and micropipette single cell measurements, ektacytometry measures bulk
RBC deformability, which has an additional parameter of cell-to-cell interaction that could
influence the overall result. Different shear rates were used in different systems, leading to
different results due to the stress-strain (as well as stress-strain rate) relationship44.
Comparing the single cell deformability results measured by microfluidic and micropipette
assays the stiffening trend differs slightly, even though both systems reported decreased
RBC deformability after ART treatment (Fig 2A & Fig 3). The microfluidic experiments
showed more significant reduction in iRBC transit velocity (50%) as compared to the drop
in uRBC transit velocity (10%). On the other hand micropipette aspiration displayed less
differentiation in uRBC (14%) and iRBC (27%) stiffening. It is possible that the
microfluidic measurement reflects the overall microcirculatory behavior of RBCs with
several determining factors including RBC geometry, intracellular fluidic viscosity, as well
as RBC membrane viscoelasticity44, whereas for the micropipette aspiration, the
contribution of cell geometry and viscosity is insignificant45, 46. Experiments measuring the
size of RBCs containing 5% parasitemia (Beckman Coulter) revealed no significant change
in RBC size after 6h ART treatment (S3), suggesting that the difference between quansi-
static and dynamic RBC deformability results may due to intracellular viscosity rather than
cell size. Heme irons are believed to be actively involved for ART's selectivity 47. Redox
chemistry of RBCs is highly complicated, involving abundant hemoglobin in RBCs. Since
parasites in iRBCs actively metabolize hemoglobin, and release high quantities of free heme
irons, this difference may lead to differential redox-response toward ART, and possibly
differentially alter the dynamic versus quasi-static deformability of iRBCs over uRBCs.
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Our study attempted to understand the impact on drug-related changes on the ring-stage
mechanical properties of P. falciparum iRBCs, by recreating the microcirculatory blood
flow in vitro using a microfluidic device, and measuring their quasi-static membrane
behavior using a micropipette device. By putting iRBCs through repeated physical and
mechanical barriers, compared with the quasi-static data, we were able to quantify the drug
related dynamic deformability modification for iRBCs and uRBCs.
In conclusion, this work demonstrates that in vitro dynamic and quasi-static deformability
measurements can be used to study subtle cell deformability changes resulting from various
environmental factors such as in vitro drug treatment. ART drug treatment on malaria
infected RBCs shows significant alternations in RBC's membrane stiffness and
microcirculatory behavior. Since human spleen is a “mechanical filter”, reduced RBC
stiffness may enhance splenic clearance of less deformable parasite iRBCs from the
circulation 24, 32. On the other hand, the drug stimulus may also aggravate the loss of uRBCs
as significant decrease in uRBC deformability was also observed in vitro. These hypotheses,
while insightful and important, are certainly yet to be further corroborated by future in vivo
and clinical studies. From the bioengineering perspectives, these measurements could
provide a well-controlled in-vitro experimental platform to test novel anti-malarial
compounds, or clarify the drug's mode of action in relation to splenic clearance, which is
generally difficult to do in vivo due to the lack of viable animal models and ethical
considerations.
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Artemisinin is an important drug for malaria treatment, but its drug mechanism remains
unclear. Past studies largely focused on the biochemistry of artemisinin to explain drug's
mechanism. In this paper, ART (artemisinin derivative)-induced change in RBC
membrane stiffness is investigated by passing RBCs through a microfluidic device that
mimics and simulates splenic filtration and other in vivo RBC deformations during
microcirculation. After ART treatment, the membrane stiffness of both healthy and
infected RBCs increases moderately (~10%), corresponding to a significant decrease in
RBC transit velocities. Our result suggests that drug-induced RBC stiffening could
significantly alter blood circulation and enhances the efficiency and specificity of splenic
parasite clearance, elucidating a previously unexplored, mechanical aspect of artemisinin
drug mechanism.
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Figure 1. Experimental schematics
A. A heating chamber (Olympus) was mounted to the inverted microscope stage. The
PDMS-glass bonded device consists of the inlet and outlet reservoirs and main channels
with triangular pillar arrays. B. Experimental images of uRBCs passing through the gaps.
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Figure 2. Artesunate (ART) effect on iRBC/uRBC dynamic deformabilities
A. 0.01 μg/ml ART was added to the RPMI cell culture medium containing 0.1 %
hematocrit. After 4 h ART incubation, the iRBC velocities with and without ART treament
were compared. B. 0.01 μg/ml ART was added to the RPMI cell culture medium containing
0.1 % hematocrit. After 2, 4, and 6 h ART incubation, the iRBC velocities were compared.
C. Time dependent ART effects on uRBC velocities were studied. D. 0.01, 0.05 and 0.10
μg/ml ART was added to the RPMI cell culure medium containing 0.1% hematocrit. After 4
h ART incubation, the concentration dependent ART effects on iRBC velocities were
compared. Black and red dots denote uRBCs and iRBCs without ART treatment whereas
black and red circles denote uRBCs and iRBCs with ART treatment respectively. Velocity
measurement on every experimental day is normalized against the average uRBC velocity in
the control sample.
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Figure 3. Artesunate effect on iRBC/uRBC membrane stiffness
0.05 μg/ml of ART were added to the RPMI cell culture medium containing 0.1%
hematocrit. After 2, 4 and 6 h of incubation with ART, micropipette aspiration of uRBCs
(black circles) and iRBCs (red circles) was carried out at a suction rate of 0.5 Pa/s. Black
dots (uRBCs) and red dots (iRBCs) represent the control without ART treatment. The mean
elastic shear moduli of the iRBCs are 30% to 40% higher than the moduli of their uninfected
counterparts. Exposure to ART results in a mild but consistent increase of the membrane
elastic shear modulus of both uRBCs and iRBCs.
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Figure 4. Pentoxifylline (PTX) effect on iRBC/uRBC dynamic deformabilities
A. 100 μg/ml PTX was added to the RPMI cell culture medium containing 0.1 %
hematocrit. After 4 h PTX incubation, the iRBC/uRBCs velocities with and without PTX
treament were compared. B. 20 and 100 μg/ml PTX was added to the RPMI cell culure
medium containing 0.1% hematocrit. After 4 h PTX incubation, the velocities of uRBCs
treated with different PTX concentrations were compared. C. 100 μg/ml PTX was added to
the RPMI cell culture medium containing 0.1% hematocrit. After 2, 4, and 6 h PTX
incubation, the uRBC velocities at different test conditions were compared. D. iRBC
velocities after 2, 4 and 6h PTX treatment were compared. No statistically significant
change in iRBC velocity can be concluded. E. PTX-ART Combination effect on RBC
deformability. No statistically significant difference can be concluded comparing RBCs
treated with ART only versus cells treated with PTX-ART combinational therapy.
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